Complete Oral ER Antagonist Compositions for Brain Metastases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for estrogen receptor (ER)-associated cancers, particularly brain metastases, are inadequate due to the inability of existing therapies like fulvestrant to cross the blood-brain barrier and achieve complete estrogen receptor antagonism, leading to poor oral bioavailability and ineffective treatment of brain tumors.
Innovation Solution
Development of complete estrogen receptor antagonists that are orally bioavailable and capable of crossing the blood-brain barrier, such as compounds with specific structural features like pyrido[3,4-b]indole and azetidinyl groups, which provide comprehensive inhibition of both AF1 and AF2 activation functions and promote ER degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fulvestrant is used to treat ER-associated cancers, then complete estrogen receptor antagonism is achieved, but the drug cannot cross the blood-brain barrier and has poor oral bioavailability
Solution Approach 1:
The patent modifies the chemical structure of fulvestrant by replacing the C-17β hydroxyl group with various substituents (aryl, heteroaryl, cycloalkyl groups) to change the drug's physicochemical properties. This structural parameter change enables the compound to cross the blood-brain barrier while maintaining complete estrogen receptor antagonism, and improves oral bioavailability without sacrificing the reliable ER antagonistic effect
2Reliability
If existing therapies are used to treat brain metastases, then treatment is provided, but invasive techniques like whole-brain radiotherapy and surgery are required
Solution Approach 1:
The patent replaces invasive mechanical treatments (surgery and whole-brain radiotherapy) with a chemically-based solution. The modified fulvestrant compounds provide a non-invasive pharmacological approach that achieves complete estrogen receptor antagonism in the brain, substituting mechanical/invasive intervention with a molecular-level therapeutic mechanism
3Reliability
If first line therapies like tamoxifen are used, then ER antagonism is provided, but patients eventually develop resistance
Solution Approach 1:
The patent extracts and eliminates the structural feature responsible for resistance development. By replacing the C-17β hydroxyl group of fulvestrant with alternative substituents, the invention creates compounds that maintain complete ER antagonism without the limitations of previous therapies, providing a solution that overcomes the resistance issue while preserving initial treatment effectiveness
Solution Approach 2:
The patent creates composite chemical structures by combining the core fulvestrant scaffold with various aryl, heteroaryl, and cycloalkyl groups. These composite molecular structures provide enhanced and sustained ER antagonism, preventing the development of resistance that occurs with simpler first-line therapies like tamoxifen
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The present disclosure provides methods of treating estrogen receptor-associated diseases, disorders, and conditions.